D. Swinney

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
D C. Swinney, David Swinney, D C Swinney, D. C. Swinney, David C. Swinney, David C Swinney
Publication record
86 papers · 4,298 citations · H-index 30

PAPERS

Recent advances in phenotypic drug discovery [version 1; peer review: 2 approved]
20223 citationsauthor #1
Successful drug discovery.
202110 citationsauthor #1
Faculty Opinions recommendation of Mining gene expression data for drug discovery.
20200 citationsauthor #1
Faculty Opinions recommendation of Image-Based Morphological Profiling Identifies a Lysosomotropic, Iron-Sequestering Autophagy Inhibitor.
20200 citationsauthor #1
Faculty Opinions recommendation of Diversity & tractability revisited in collaborative small molecule phenotypic screening library design.
20200 citationsauthor #1
Faculty Opinions recommendation of The convergence of stem cell technologies and phenotypic drug discovery.
20200 citationsauthor #1
Recent advances in phenotypic drug discovery
202046 citationsauthor #1
Chapter 1. Phenotypic Drug Discovery: History, Evolution, Future
20202 citationsauthor #1
Faculty Opinions recommendation of Target 2035: probing the human proteome.
20200 citationsauthor #1
Faculty Opinions recommendation of Synergistic effects of stereochemistry and appendages on the performance diversity of a collection of synthetic compounds.
20200 citationsauthor #1
Faculty Opinions recommendation of The power of combining phenotypic and target-focused drug discovery.
20200 citationsauthor #1
Faculty Opinions recommendation of Structural basis of a small molecule targeting RNA for a specific splicing correction.
20200 citationsauthor #1
Fluxes for Unraveling Complex Binding Mechanisms.
20205 citationsauthor #3
Faculty Opinions recommendation of Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective.
20200 citationsauthor #1
Faculty Opinions recommendation of A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.
20200 citationsauthor #1
Faculty Opinions recommendation of Glimmers in illuminating the druggable genome.
20200 citationsauthor #1
Development of a Bioluminescent High-Throughput Screening Assay for Nicotinamide Mononucleotide Adenylyltransferase (NMNAT)
201910 citationsauthor #3
Drug Discovery Strategies for Neglected Tropical Diseases: Repurposing Knowledge, Mechanisms and Therapeutics to Increase Discovery Efficiency
20194 citationsauthor #1
Pharmaceutical Industry Performance
20171 citationsauthor #1
Insights into kinetic mechanism of Janus kinase 3 and its inhibition by tofacitinib.
20162 citationsauthor #7
Glycogen Synthase Kinase 3β Promotes the Endocytosis of Transferrin in the African Trypanosome.
201613 citationsauthor #3
A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β
201616 citationsauthor #8
Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates.
201621 citationsauthor #2
Correction: Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B
20160 citationsauthor #7
On the different experimental manifestations of two‐state ‘induced‐fit’ binding of drugs to their cellular targets
201617 citationsauthor #3
Experimental Methods to Determine Binding Kinetics
20156 citationsauthor #3
The Role of Binding Kinetics in GPCR Drug Discovery.
201547 citationsauthor #1
Thermodynamics and Kinetics of Drug Binding: Keserü/Thermodynamics and Kinetics of Drug Binding
201524 citationsauthor #2
Thermodynamics and Binding Kinetics in Drug Discovery
20152 citationsauthor #2
Drug Discoveries and Molecular Mechanism of Action
20155 citationsauthor #1
Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B
201544 citationsauthor #7
Radioligand binding to intact cells as a tool for extended drug screening in a representative physiological context.
201511 citationsauthor #3
The value of translational biomarkers to phenotypic assays
201420 citationsauthor #1
Collaboration for rare disease drug discovery research
201429 citationsauthor #3
The discovery of medicines for rare diseases.
201428 citationsauthor #1
Opportunities for phenotypic screening_Layout 1
20140 citationsauthor #1
A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands
201458 citationsauthor #1
The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.
201463 citationsauthor #10
Contrasting Roles of Mitogen-Activated Protein Kinases in Cellular Entry and Replication of Hepatitis C Virus: MKNK1 Facilitates Cell Entry
201331 citationsauthor #5
Where did drugs come from
20130 citationsauthor #1
The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines
201364 citationsauthor #1
Applications of Binding Kinetics to Drug Discovery
201252 citationsauthor #1
Transcriptomic analysis of the woodchuck model of chronic hepatitis B
2012102 citationsauthor #6
Kinetic Binding Mechanisms: Their Contribution to an Optimal Therapeutic Index
20119 citationsauthor #1
How were new medicines discovered?
20111,649 citationsauthor #1
3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
201129 citationsauthor #23
Molecular Mechanism of Action (MMoA) in Drug Discovery
201139 citationsauthor #1
Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deaza-adenosine triphosphate.
201044 citationsauthor #17
Steady-state kinetic characterization of kinase activity and requirements for Mg2+ of interleukin-1 receptor-associated kinase-4.
20108 citationsauthor #3
Pre-Steady-State Kinetic Analysis of the Elongation Mode of Dengue Virus RNA Polymerase Domain
20100 citationsauthor #4
The role of binding kinetics in therapeutically useful drug action.
2009180 citationsauthor #1
Essential Role of the N-terminal Domain in the Regulation of RIG-I ATPase Activity*
200868 citationsauthor #6
Kinetic characterization of human JNK2alpha2 reaction mechanism using substrate competitive inhibitors.
200724 citationsauthor #6
Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay.
200725 citationsauthor #8
Activation Mechanism and Steady State Kinetics of Bruton's Tyrosine Kinase*
200743 citationsauthor #9
Opportunities to minimise risk in drug discovery and development
20063 citationsauthor #1
Kinetic characterization of JNK reaction mechanism using substrate competitive inhibitors
20060 citationsauthor #6
Biochemical Mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001‐2004: Mechanisms leading to optimal efficacy and safety.
200690 citationsauthor #1
Cigarette smoke synergistically enhances respiratory mucin induction by proinflammatory stimuli.
2006113 citationsauthor #4
Assay to evaluate factors that contribute to the correlation between enzyme and cellular potency for ATP competitive inhibitors of p38 kinase
20060 citationsauthor #3
Real‐time measurement of dissociation rates of unlabeled compounds from a membrane receptor
20060 citationsauthor #6
Editorial [Hot Topic:Successful Drug Discovery: Rules and Examples (Guest Editor: Dr. David C. Swinney)]
20060 citationsauthor #1
Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice
200655 citationsauthor #1
Bi-substrate kinetic analysis of an E3-ligase-dependent ubiquitylation reaction.
20054 citationsauthor #1
Biochemical mechanisms of drug action: what does it take for success?
2004371 citationsauthor #1
A Small Molecule Ubiquitination Inhibitor Blocks NF-κB-dependent Cytokine Expression in Cells and Rats*
200286 citationsauthor #1
Targeting protein ubiquitination for drug discovery. What is in the drug discovery toolbox?
200112 citationsauthor #1
Structural Characterization of Arachidonyl Radicals Formed by Prostaglandin H Synthase-2 and Prostaglandin H Synthase-1 Reconstituted with Mangano Protoporphyrin IX*
199866 citationsauthor #4
The Dynamics of Prostaglandin H Synthases
199887 citationsauthor #5
Arachidonate oxidation by peroxide-induced tyrosyl radicals in both prostaglandin H synthase (PGHS) isozymes
19970 citationsauthor #4
Differential Allosteric Regulation of Prostaglandin H Synthase 1 and 2 by Arachidonic Acid*
1997106 citationsauthor #1
The Kinetic Factors That Determine the Affinity and Selectivity for Slow Binding Inhibition of Human Prostaglandin H Synthase 1 and 2 by Indomethacin and Flurbiprofen (*)
199680 citationsauthor #3
Azalanstat (RS-21607), a lanosterol 14α-demethylase inhibitor with cholesterol-lowering activity
199530 citationsauthor #2
Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity.
19958 citationsauthor #2
Selective inhibition of mammalian lanosterol 14 alpha-demethylase by RS-21607 in vitro and in vivo.
199435 citationsauthor #1
Accumulation of intermediates and isotopically sensitive enolization distinguish between aromatase (cytochrome P450 CYP19) from rat ovary and human placenta.
199315 citationsauthor #1
Cyclosporine metabolism by rat liver microsomes. Evidence for involvement of enzyme(s) other than cytochromes P-450 3A.
199338 citationsauthor #4
Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
199330 citationsauthor #4
Stereoisomers of ketoconazole: preparation and biological activity.
1992116 citationsauthor #4
17-O-Acetyltestosterone formation from progesterone in microsomes from pig testes: evidence for the Baeyer-Villiger rearrangement in androgen formation catalyzed by CYP17
199226 citationsauthor #2
Cholesterol decreasing agent
19910 citationsauthor #2
A novel rat hepatic clofibrate-inducible cytochrome P450 that is not a lauric acid hydroxylase.
19916 citationsauthor #1
Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P-450 inhibitor, ketoconazole, and the NADPH 5 alpha-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog, and rat.
199032 citationsauthor #1
Evidence for concerted kinetic oxidation of progesterone by purified rat hepatic cytochrome P-450g.
198823 citationsauthor #1
The synthesis of deuterium labelled metabolites of warfarin and phenprocoumon
198611 citationsauthor #4
Intramolecular isotope effects associated with meta-hydroxylation of biphenyl catalyzed by cytochrome P-450.
19845 citationsauthor #1

TIMELINE

1984 5 citations

1986 11 citations

1988 23 citations

1990 32 citations

1991 6 citations

1992 142 citations

1993 83 citations

1994 35 citations

1995 38 citations

1996 80 citations

1997 106 citations

1998 153 citations

2001 12 citations

2002 86 citations

2004 371 citations

2005 4 citations

2006 261 citations

2007 92 citations

2008 68 citations

2009 180 citations

2010 52 citations

2011 1,726 citations

2012 154 citations

2013 95 citations

2014 198 citations

2015 139 citations

2016 69 citations

2017 1 citations

2019 14 citations

2020 53 citations

2021 10 citations

2022 3 citations

D. Swinney

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT